Previous 10 | Next 10 |
Bicycle Therapeutics (NASDAQ:BCYC): Q3 GAAP EPS of -$0.59 beats by $0.03. Revenue of $4.33M (+12.8% Y/Y) misses by $1.42M. Press Release For further details see: Bicycle Therapeutics EPS beats by $0.03, misses on revenue
Bicycle Therapeutics (NASDAQ:BCYC) announces that the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT7480, a novel, fully synthetic Bicycle tumor-targeted immune cell agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD13...
- Announced interim BT5528 Phase I clinical trial results and preliminary results from ongoing BT8009 Phase I clinical trial - First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Asso...
- BT7480 is the Company’s Fourth Product Candidate to Enter the Clinic in the Past Four Years - This is Bicycle’s First Immuno-oncology Asset to Enter the Clinic Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and diffe...
Ionis Pharmaceuticals (NASDAQ:IONS) saw its net loss increase ~122% in Q3 2021 year over year to ~$82M driven by costs related to restructured commercial operations and a boost in R&D expenses to advance its pipeline. R&D expenses increased 48% to $185M. Ionis said this figure include...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that an article highlighting preclinical data from BT7480, a tumor-targe...
Genentech exercised an option to initiate an additional program under the 2020 collaboration agreement Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bic...
Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the closing on Friday, October 15, 2021 of its underwritten public ...
Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the pricing of an underwritten public offering of 3,240,741 America...
Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that it has commenced an underwritten public offering of $125,000,0...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...
Financing includes participation from new and existing investors Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the second half of 2027 Supports ongoing advancement of pipeline with multiple clinical-...